These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23607665)

  • 1. Targets for anti-metastatic drug development.
    Stock AM; Troost G; Niggemann B; Zänker KS; Entschladen F
    Curr Pharm Des; 2013; 19(28):5127-34. PubMed ID: 23607665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-metastatics: an overview of drug candidates in current pipelines.
    Schaap-Nutt A; Thyssen DA; Drell DW; Entschladen F
    Curr Pharm Des; 2014; 20(42):6522-8. PubMed ID: 25341929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development.
    Entschladen F; Drell TL; Lang K; Joseph J; Zaenker KS
    Curr Pharm Des; 2005; 11(3):403-11. PubMed ID: 15723634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future approaches for the therapeutic targeting of metastasis (review).
    Germanov E; Berman JN; Guernsey DL
    Int J Mol Med; 2006 Dec; 18(6):1025-36. PubMed ID: 17089005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate).
    Alam F; Al-Hilal TA; Park J; Choi JU; Mahmud F; Jeong JH; Kim IS; Kim SY; Hwang SR; Byun Y
    Biomaterials; 2016 Apr; 86():56-67. PubMed ID: 26890038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.
    Gandalovičová A; Rosel D; Fernandes M; Veselý P; Heneberg P; Čermák V; Petruželka L; Kumar S; Sanz-Moreno V; Brábek J
    Trends Cancer; 2017 Jun; 3(6):391-406. PubMed ID: 28670628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.
    Lappano R; Maggiolini M
    Drugs; 2017 Jun; 77(9):951-965. PubMed ID: 28401445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis.
    Uekita T; Sakai R
    Cancer Sci; 2011 Nov; 102(11):1943-8. PubMed ID: 21812858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptors.
    Lymperopoulos A
    Curr Pharm Des; 2012; 18(2):192-8. PubMed ID: 22229558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy.
    Chambers AF; MacDonald IC; Schmidt EE; Morris VL; Groom AC
    Cancer Metastasis Rev; 1998-1999; 17(3):263-9. PubMed ID: 10352879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic targets in melanoma.
    Martí RM; Sorolla A; Yeramian A
    Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological strategies and micrometastasis: what is known? What must be done?
    Perret GY
    Minerva Med; 2010 Jun; 101(3):163-78. PubMed ID: 20562804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of G Protein-coupled Receptor Kinases in Cancer.
    Yu S; Sun L; Jiao Y; Lee LTO
    Int J Biol Sci; 2018; 14(2):189-203. PubMed ID: 29483837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.